STOCK TITAN

Medicus Pharma Ltd. (MDCX) SEC Filings, Nov 4-17, 2026

MDCX NASDAQ

The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.

Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.

Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.

Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.

How Stock Titan helps

Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.

Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) President and CFO Carolyn F. Bonner acquired 29,069 common shares on November 13, 2026, at $1.72 per share. She held 58,859 common shares directly after the transaction. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
-
Rhea-AI Summary

Raza Bokhari reported acquisition or exercise transactions in this Form 4 filing. Medicus Pharma Ltd. (MDCX) reports that RBx Capital, LP, an entity controlled by Chief Executive Officer, director and 10% owner Raza Bokhari, entered a subscription agreement to purchase 436,046 common shares at $1.72 per share in a private placement on November 13, 2026. RBx Capital reported 451,909 common shares following the transaction. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
insider
-
Rhea-AI Summary

Medicus Pharma Ltd.'s prospectus supplement covers 64,911 common shares issuable upon exercise of warrants and incorporates the company's November 13, 2026 current-report update.

Medicus exchanged $10.5 million of A-1 Note principal for 105,000 non-convertible, non-voting preferred shares at $100 each; the exchanged debt was extinguished, with no cash proceeds to the company. The preferred shares carry cumulative 8% annual dividends payable in kind. A separate registered direct offering closed with approximately $3.0 million in gross proceeds before expenses, excluding warrant-exercise proceeds; the company also completed private placements for approximately $1.25 million and ATM sales for approximately $0.35 million.

After these transactions, the company estimated unaudited pro forma shareholders' equity of approximately $3.0 million as of November 13, 2026, and believes it met Nasdaq's $2.5 million Equity Standard. Nasdaq had not confirmed compliance; the company may be subject to delisting if it does not evidence compliance at its next periodic report. Medicus also cited substantial doubt about its ability to continue as a going concern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
prospectus
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) completed a debt-for-equity exchange and financing on November 13, 2026. It exchanged $10.5 million of A-1 Note principal for 105,000 non-convertible, non-voting preferred shares at $100 each, with no cash proceeds. The shares carry cumulative 8% annual dividends payable in additional preferred shares. Its registered direct offering closed with 97,973 common shares at $1.72 and pre-funded warrants for up to 1,646,213 shares at $1.7199 each, generating approximately $3.0 million in gross proceeds before expenses, excluding warrant exercise proceeds.

Concurrent private placements involved 726,730 common shares and approximately $1.25 million in gross proceeds. Since the quarter ended September 30, ATM sales through November 12 totaled approximately 113,000 shares for approximately $0.35 million gross. Medicus estimates unaudited pro forma shareholders’ equity of approximately $3.0 million as of November 13 and believes it meets Nasdaq’s $2.5 million Equity Standard. Nasdaq has not confirmed compliance; failure to evidence it at the next periodic report may lead to delisting. Approximately $4.2 million of principal and accrued unpaid interest remains outstanding under the A Notes; $8.2 million under Note B was unaffected.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
current report
-
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) is offering 97,973 common shares and pre-funded warrants to purchase up to 1,646,213 common shares, at $1.72 per share and $1.7199 per warrant. Each warrant covers one share, is immediately exercisable at $0.0001 per share, and carries a 4.99% beneficial-ownership limit, or 9.99% at the holder’s election. Gross proceeds are approximately $3.0 million before expenses, excluding warrant-exercise proceeds.

Closing depends on a concurrent private placement of 726,730 shares for approximately $1.25 million, including at least $1.1 million in gross cash proceeds at no less than $1.72 per share, funded from purchasers’ own resources rather than conversion or cancellation of company obligations. Separately, Streeterville exchanged $10.5 million principal under the A-1 Note for 105,000 non-convertible, non-voting preferred shares; the exchanged debt was extinguished, and the preferred shares carry cumulative 8% dividends payable in kind.

Medicus disclosed substantial doubt about its ability to continue as a going concern. As of September 30, 2026, it had approximately $5.0 million in cash and equivalents, $8.1 million in restricted cash and $21.0 million in debentures and secured notes by carrying amount. The company says the offering and private-placement proceeds, together with existing cash, will not fund planned operations for an extended period and that it needs substantial additional capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
prospectus
-
Rhea-AI Summary

Medicus Pharma Ltd. reported nine-month results and outlined its Pfizer license for CD228V and the proposed SkinJect business combination. The Pfizer agreement grants an exclusive worldwide license, subject to retained rights, to develop, manufacture and commercialize CD228V; Pfizer provided $2 million for development and may elect, without obligation, to fund all or part of development beginning with the first pivotal trial. SkinJect’s non-binding letter of intent contemplates a $135 million pre-money enterprise valuation, equity financing at closing and an approximately $3 million program budget over the next two years. The SPAC would acquire 100% of SkinJect for newly issued shares; Medicus seeks majority economic and voting ownership and anticipates completion in the first half of 2027, with no assurance of closing.

For the nine months ended September 30, 2026, operating expenses were $34.5 million versus $26.6 million, including a $10.0 million acquired IPR&D charge; net loss was $35.9 million versus $27.3 million. Third-quarter operating expenses were $14.5 million versus $15.4 million, and net loss was $15.2 million versus $16.0 million. Medicus raised approximately $42.5 million through equity and secured debt financings, net of issuance costs; net cash provided by financing activities was $36.2 million after approximately $6.4 million of debt repayments. September 30 combined cash, cash equivalents and restricted cash was $13.1 million; liabilities were $25 million versus $10 million at December 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
merger
Rhea-AI Summary

Medicus Pharma Ltd. (MDCX) reported third-quarter 2026 results and named CD228V its principal development priority following a co-development and license agreement with Pfizer. Pfizer provided $2.0 million in development funding and may, without obligation, elect to fund development beginning with the first pivotal trial, subject to a further definitive agreement.

As of September 30, 2026, cash, cash equivalents and restricted cash totaled $13.1 million; cash and cash equivalents were $5.0 million versus $8.7 million as of December 31, 2025. Net loss was $15.2 million, compared with $16.0 million in Q3 2025. SkinJect has a non-binding LOI for a proposed SPAC combination at an approximate $135 million pre-money enterprise valuation, with a contemplated concurrent closing financing. The FDA issued a “Study May Proceed” letter for SkinJect’s SKNJCT-005 study. Medicus submitted a proposed Teverelix protocol for approximately 608 patients, subject to continuation criteria and FDA feedback.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.80%
Tags
merger
-
Rhea-AI Summary

Medicus Pharma Ltd. supplements its prospectus with 3,245,595 common shares issuable upon exercise of warrants. Its Public Warrants carry a $4.64 exercise price and expire November 15, 2029. For the nine months ended September 30, 2026, Medicus recorded a net loss of $35.9 million, compared with $27.3 million in 2025, and used $31.9 million in operating cash, versus $16.2 million. At September 30, cash and cash equivalents were $5.0 million and restricted cash was $8.1 million; the restricted funds were not available for general corporate purposes except under the financing arrangements.

The company disclosed substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued, citing continued losses and outstanding debt obligations. It expects significant operating losses and may never become profitable. Under its Pfizer agreement, Medicus paid $12.0 million upfront for CD228V rights; a $2.0 million development funding payment reduced the related acquired IPR&D expense to $10.0 million. A further $15.0 million payment is scheduled for September 2, 2027, unless the company exercises its termination right under the stated conditions. Third-quarter net loss was $15.2 million versus $16.0 million a year earlier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.80%
Tags
prospectus
-
Rhea-AI Summary

Medicus Pharma Ltd. reported a net loss of $15,172,908 for the quarter ended September 30, 2026, versus $15,981,312 a year earlier; nine-month net loss was $35,899,646, compared with $27,259,804. Quarterly operating expenses were $14,460,256, including $10,000,000 of net acquired IPR&D expense for CD228V.

CD228V became the company's principal development priority. Medicus paid Pfizer $12.0 million upfront for CD228V rights and received $2.0 million in development funding, recorded against acquired IPR&D expense. A further $15.0 million payment is due September 2, 2027, unless termination notice is provided by June 4, 2027, before the first Phase 1 patient is dosed; if dosing occurs earlier, at least 90 days' notice is required before dosing.

Nine-month operating cash use was $31,893,868. At September 30, cash and cash equivalents were $5,019,755 and restricted cash was $8,075,075. Management said substantial doubt exists about continuing as a going concern within one year after the financial statements are issued. The 50-to-1 consolidation took effect October 12, reducing issued and outstanding shares from 93,770,921 to 1,850,418; the company reported regaining Nasdaq minimum-bid compliance on October 23.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.80%
Tags
quarterly report
Rhea-AI Summary

Medicus Pharma Ltd. announced that its wholly owned subsidiary, SkinJect, Inc., entered a non-binding letter of intent with an undisclosed special purpose acquisition company (SPAC) for a proposed business combination. The LOI contemplates a $135 million pre-money enterprise valuation and concurrent equity financing to support the SKNJCT-005 study in Gorlin syndrome and preparation and submission of a potential NDA. Under the proposed terms, the SPAC would acquire 100% of SkinJect for newly issued shares of the combined company; Medicus seeks to retain majority economic and voting ownership.

Except for limited procedural provisions, the terms are non-binding. Completion is subject to due diligence, definitive agreements, financing, a minimum-cash condition, board and shareholder approvals, SEC filings and registration, stock-exchange listing approval and other agreed conditions. Medicus anticipates completion in the first half of 2027, although there is no assurance it will close in that timeframe or at all. The FDA issued a “Study May Proceed” letter authorizing initiation of the planned NDA-enabling registrational Phase 2b study. Medicus also scheduled a business update call for November 9, 2026, at 11:30 a.m. Eastern Time, following its 10-Q for the quarter ended September 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
current report

FAQ

How many Medicus Pharma Ltd. (MDCX) SEC filings are available on StockTitan?

StockTitan tracks 189 SEC filings for Medicus Pharma Ltd. (MDCX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Medicus Pharma Ltd. (MDCX)?

The most recent SEC filing for Medicus Pharma Ltd. (MDCX) was filed on November 19, 2026.